Clinical trials: Metabolism
Obesity &Amp; Overweight
A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy, overweight, and obese subjects. The primary objective is to evaluate the effect of orally administered VCT220 tablets on the…
- Trial name
- NCT07065058
- Testing
- Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Pain
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain
This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic…
- Trial name
- NEPTUNE-17 (NCT05838755)
- Testing
- GSK3858279
- Where
- 81 sites in United States, Canada and 9 more
- Volunteers
- 147 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Heart Frequency in Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate if liraglutide effects the QTc interval. Moxifloxacin (Avelox®) is administered as positive control.
- Trial name
- NCT01516255
- Testing
- liraglutide, moxifloxacin, electrocardiogram (ECG)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects
The primary purpose of this study is to determine the safety and tolerability of SRT2104 (0.25, 0.5, 1.0, and 2.0 g/day) in type 2 diabetic subjects when administered once daily for 28 consecutive days, and to characterize the…
- Trial name
- NCT00937326
- Testing
- SRT2104
- Where
- 61 sites in Bulgaria, Estonia and 6 more
- Volunteers
- 227 people
- Sponsor
- Sirtris, a GSK Company
Diabetes Mellitus
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
A multicenter, randomized, double-blind, placebo-controlled trial will assess the effects of twice-daily subcutaneous injection with exenatide versus treatment with matching placebo injection on abdominal visceral fat content.
- Trial name
- NCT00701935
- Testing
- exenatide
- Where
- 17 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.
- Trial name
- NCT01131676
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 615 sites in United States, Argentina and 40 more
- Volunteers
- 7,064 people
- Sponsor
- Boehringer Ingelheim
Gout
PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who are beginning allopurinol treatment for gout.
- Trial name
- NCT00958438
- Testing
- Rilonacept
- Where
- 61 sites in Germany, India and 3 more
- Volunteers
- 248 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity, Adiposity
Endoscopic Gastric Mucosal Ablation as a Primary Obesity Therapy
This study is intended to investigate safety and feasibility of a new weight loss technique called endoscopic Gastric Mucosal Ablation (GMA) that does not require surgery, but can be achieved using an endoscopic procedure.
- Trial name
- COMET (NCT05486338)
- Testing
- Hybrid Argon Plasma Coagulation (HAPC)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Erbe Elektromedizin GmbH
Diabetes Mellitus, Type 2
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months.
- Trial name
- SURE GERMANY (NCT04261933)
- Testing
- semaglutide
- Where
- 95 sites in Germany
- Volunteers
- 789 people
- Sponsor
- Novo Nordisk A/S
Hypercholesterolemia
The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients
To evaluate efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients
- Trial name
- NCT02251847
- Testing
- Rosuvastatin/Ezetimibe
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Diabetes Mellitus, Type 1
A Study in Adults With Type 1 Diabetes
The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day.
- Trial name
- ELEMENT 1 (NCT01421147)
- Testing
- LY2963016, Lantus, Insulin Lispro
- Where
- 52 sites in United States, Belgium and 7 more
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company
Hypertension
Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat
This was a Phase 1, open-label, single dose study in healthy male subjects. The goals of this clinical trial were to determine how baxdrostat might be absorbed and metabolized using radioactive [14C] labeled baxdrostat.
- Trial name
- NCT05961384
- Testing
- baxdrostat
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
CKD, Low Protein Dietary Intake
Suitability of a High-energy, Low-protein Formula (Renalive® LP)
Inclusion criteria (1) Diagnosed with chronic kidney disease stage 3b-5 (with history of eGFR<45 mL/min/1.73 m2) Exclusion criteria (1) Has received dialysis or are expected to start dialysis within the next 3 months.
- Conditions
- CKD, Low Protein Dietary Intake, Malnutrition (Calorie)
- Trial name
- NCT06892249
- Testing
- Renalive® LP,
- Where
- 2 sites in Taiwan
- Volunteers
- 80 people
- Sponsor
- Fresenius Kabi Taiwan Ltd.
Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)
PATHWAY is a Phase 2b/3 clinical study with an Open-Label Extension (OLE). It tests PORT-77 in patients with EPP, EPP2, and XLP.
- Conditions
- Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP), EPP2
- Trial name
- PATHWAY (NCT07820085)
- Testing
- PORT-77
- Where
- 2 sites in United States
- Volunteers
- 225 people
- Sponsor
- Portal Therapeutics, Inc.
Diabetes Mellitus, Type 2
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
The purpose of the study is to determine the effect of glimepiride on dapagliflozin and the effect of dapagliflozin on glimepiride in healthy volunteers.
- Trial name
- NCT00562250
- Testing
- Dapagliflozin, Glimepiride, Dapagliflozin + Glimepiride
- Where
- Argentina
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes
This study has two parts. Each participant will receive a daily injection of insulin peglispro during one treatment period and a daily injection of insulin glargine during the other treatment period.
- Trial name
- NCT01771250
- Testing
- Insulin Peglispro, Insulin Glargine
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Human Insulin NPH and Insulin Aspart in Type 1 Diabetes
This trial is conducted in South America. This aim of this trial is to evaluate the comparative prandial blood glucose lowering profile in subjects with type 1 diabetes.
- Trial name
- NCT00597233
- Testing
- insulin aspart, soluble human insulin, insulin NPH
- Where
- Argentina
- Volunteers
- 91 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)
A study to assess the efficacy and tolerability of ER (Extended Release) niacin/laropiprant versus placebo in Type 2 Diabetes Mellitus patients.
- Trial name
- NCT00485758
- Testing
- ER niacin/laropiprant
- Volunteers
- 796 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Hypercholesterolemia, Mixed Dyslipidemia
Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
This study is being done to learn more about evolocumab in Chinese people with primary hypercholesterolemia or mixed dyslipidemia.
- Trial name
- NCT03433755
- Testing
- evolocumab
- Where
- 31 sites in China
- Volunteers
- 259 people
- Sponsor
- Amgen
Obese, Sleep Apnea, Obstructive
Eval EarlySense Bet Lowenstein Sleeplab
The study objective is to collect heart rate, respiration rate and motion data of patients admitted to sleep lab and to determine the accuracy level of the EarlySense system vs.
- Conditions
- Obese, Sleep Apnea, Obstructive, Central Apnea, Sleep Disorders
- Trial name
- NCT01978340
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- EarlySense Ltd.